Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Get Free Report) insider Neal Flomenberg sold 14,639 shares of Tevogen Bio stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $1.28, for a total value of $18,737.92. Following the completion of the sale, the insider now directly owns 4,239,663 shares of the company's stock, valued at approximately $5,426,768.64. This represents a 0.34 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Neal Flomenberg also recently made the following trade(s):
- On Thursday, March 6th, Neal Flomenberg sold 88,519 shares of Tevogen Bio stock. The stock was sold at an average price of $1.10, for a total value of $97,370.90.
Tevogen Bio Stock Down 7.6 %
NASDAQ:TVGN opened at $1.10 on Friday. The firm's 50 day moving average is $1.35 and its two-hundred day moving average is $1.15. Tevogen Bio Holdings Inc. has a fifty-two week low of $0.26 and a fifty-two week high of $7.73.
Analysts Set New Price Targets
Separately, D. Boral Capital started coverage on shares of Tevogen Bio in a research note on Tuesday. They set a "buy" rating and a $10.00 price objective for the company.
Check Out Our Latest Analysis on Tevogen Bio
Institutional Investors Weigh In On Tevogen Bio
Institutional investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. purchased a new position in shares of Tevogen Bio in the 4th quarter worth about $38,000. JPMorgan Chase & Co. grew its holdings in shares of Tevogen Bio by 74.2% during the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company's stock worth $40,000 after purchasing an additional 16,695 shares during the period. Barclays PLC increased its position in Tevogen Bio by 39.2% during the 4th quarter. Barclays PLC now owns 45,600 shares of the company's stock worth $48,000 after purchasing an additional 12,847 shares in the last quarter. XTX Topco Ltd purchased a new position in Tevogen Bio in the fourth quarter valued at approximately $55,000. Finally, HGC Investment Management Inc. acquired a new position in Tevogen Bio during the third quarter valued at approximately $82,000.
Tevogen Bio Company Profile
(
Get Free Report)
Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
